Sign in Subscribe

Immunocore’s Kimmtrak Anchors Growth as Pipeline Eyes Bigger Markets

Immunocore’s Kimmtrak hit ~$400M in 2025 sales with strong 2026 momentum. Solid cash, advancing Phase 3 trials, and Wall Street Buy ratings signal further upside.

Immunocore’s Kimmtrak Anchors Growth as Pipeline Eyes Bigger Markets
Credit: Understanding Cancer Immunotherapy Research
Already have an account? Sign in.